Open Collections

UBC Faculty Research and Publications

Managing Select Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitors Cheema, Parneet K.; Iafolla, Marco A. J.; Abdel-Qadir, Husam; Bellini, Andrew B.; Chatur, Nazira; Chandok, Natasha; Comondore, Vikram R.; Cunningham, Morven; Halperin, Ilana; Hu, Anne B.; Jaskolka, Diana; Darvish-Kazem, Saeed; Khandaker, Masud H.; Kitchlu, Abhijat; Sachdeva, Jasdip S.; Shapera, Shane; Woolnough, Nicholas R. J.; Nematollahi, Massey

Abstract

The increased use of immune checkpoint inhibitors (ICIs) across cancer programs has created the need for standardized monitoring and management of immune-related adverse events (irAEs). Delayed recognition without appropriate treatment can have serious and life-threatening consequences. The management of irAEs presents a unique set of challenges that must be addressed at a multidisciplinary level. Although various national and international guidelines and working groups provide high-level recommendations for the management of irAEs, practical guidance is lacking. Furthermore, timely collaboration between specialists requires institutional protocols that enable the early recognition, assessment, and treatment of irAEs. Such protocols should be developed by institution specialists and include algorithms for all healthcare providers involved in the care of patients treated with ICIs. At William Osler Health System in Brampton, Ontario, practical step-by-step multidisciplinary treatment approaches with recommendations for the management of irAEs were developed in collaboration with experts across Canada. Here, we provide an in-depth description of the approaches, outlining baseline investigations prior to the initiation of ICIs, as well as the monitoring and management of irAEs based on symptoms, severity, and involved organ systems. We encourage other centres to adapt and modify our approaches according to their specific needs and requirements.

Item Metadata

Title
Managing Select Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitors
Creator
Cheema, Parneet K.; Iafolla, Marco A. J.; Abdel-Qadir, Husam; Bellini, Andrew B.; Chatur, Nazira; Chandok, Natasha; Comondore, Vikram R.; Cunningham, Morven; Halperin, Ilana; Hu, Anne B.; Jaskolka, Diana; Darvish-Kazem, Saeed; Khandaker, Masud H.; Kitchlu, Abhijat; Sachdeva, Jasdip S.; Shapera, Shane; Woolnough, Nicholas R. J.; Nematollahi, Massey
Publisher
Multidisciplinary Digital Publishing Institute
Date Issued
2024-10-18
Description
The increased use of immune checkpoint inhibitors (ICIs) across cancer programs has created the need for standardized monitoring and management of immune-related adverse events (irAEs). Delayed recognition without appropriate treatment can have serious and life-threatening consequences. The management of irAEs presents a unique set of challenges that must be addressed at a multidisciplinary level. Although various national and international guidelines and working groups provide high-level recommendations for the management of irAEs, practical guidance is lacking. Furthermore, timely collaboration between specialists requires institutional protocols that enable the early recognition, assessment, and treatment of irAEs. Such protocols should be developed by institution specialists and include algorithms for all healthcare providers involved in the care of patients treated with ICIs. At William Osler Health System in Brampton, Ontario, practical step-by-step multidisciplinary treatment approaches with recommendations for the management of irAEs were developed in collaboration with experts across Canada. Here, we provide an in-depth description of the approaches, outlining baseline investigations prior to the initiation of ICIs, as well as the monitoring and management of irAEs based on symptoms, severity, and involved organ systems. We encourage other centres to adapt and modify our approaches according to their specific needs and requirements.
Subject
immune checkpoint inhibitors; immune-related adverse events; immunosuppressants
Genre
Article
Type
Text
Language
eng
Date Available
2024-10-28
Provider
Vancouver : University of British Columbia Library
Rights
CC BY 4.0
DOI
10.14288/1.0447161
URI
http://hdl.handle.net/2429/89561
Affiliation
Medicine, Faculty of; Non UBC
Citation
Current Oncology 31 (10): 6356-6383 (2024)
Publisher DOI
10.3390/curroncol31100473
Peer Review Status
Reviewed
Scholarly Level
Faculty; Researcher
Rights URI
https://creativecommons.org/licenses/by/4.0/
Aggregated Source Repository
DSpace

Item Media

Item Citations and Data

Rights

CC BY 4.0